Thus, concomitant inhibition of FAK and TGF-β signaling using either TGF-β-RI kinase inhibitors (such as galunisertib) or monoclonal antibodies (such as frezolizumab) may act synergistically in pancreatic cancer. Here, TGFB1 is linked to pancreatic neoplasm.